For the first time in decades, multiple new pancreatic cancer drugs are demonstrating genuine survival benefits in clinical trials, offering a measure of hope for a disease that has long resisted meaningful treatment advances. The most striking result comes from elraglusib, a GSK-3β inhibitor developed by Actuate Therapeutics, which doubled 12-month overall survival from 22.3% to 44.4% when added to standard chemotherapy in a Phase 2 trial of 233 patients with previously untreated metastatic pancreatic cancer. That data, presented at ASCO GI 2026 in January, showed a median overall survival of 10.1 months with the combination versus 7.2 months with chemotherapy alone — a statistically significant 38% reduction in the risk of death. These findings do not exist in isolation.
The FDA has already approved Optune Pax, a wearable device delivering tumor treating fields, for locally advanced pancreatic cancer — the first new approved treatment for that indication in nearly 30 years. Meanwhile, daraxonrasib, a novel RAS inhibitor from Revolution Medicines, has earned FDA Breakthrough Therapy Designation after showing that more than 90% of patients experienced disease stabilization in early trials. For readers of this site who are navigating the overlap between cancer care and cognitive health — whether as caregivers managing multiple diagnoses or patients dealing with chemotherapy’s neurological effects — these developments matter in concrete, practical ways. This article examines each of these emerging treatments in detail, including their mechanisms, trial results, limitations, and what they mean for patients and families already stretched thin by the demands of serious illness.
Table of Contents
- What New Pancreatic Cancer Drugs Are Showing Real Signs of Survival Benefit?
- How Optune Pax Became the First FDA-Approved Advance in Nearly Three Decades
- The KRAS Revolution and What It Means for Targeted Pancreatic Cancer Treatment
- Comparing Survival Numbers Across Treatments — What Patients and Families Should Actually Expect
- Side Effects, Cognitive Concerns, and the Caregiver Burden
- How Immune Activation From New Drugs Could Affect Brain Health
- What Comes Next — Trials to Watch and the Changing Outlook
- Conclusion
- Frequently Asked Questions
What New Pancreatic Cancer Drugs Are Showing Real Signs of Survival Benefit?
The landscape has shifted from a single promising agent to a small but meaningful cluster of drugs attacking pancreatic cancer through different biological pathways. Elraglusib works by inhibiting GSK-3β, a kinase involved in cancer cell survival and immune evasion. What makes the Actuate-1801 trial results particularly notable is not just the survival numbers but the immunological evidence behind them: tumors treated with elraglusib showed elevated CD8+ T cells, NK cells, and Granzyme B+ cells, suggesting the drug is genuinely activating the immune system against the cancer rather than simply slowing tumor growth. Three patients in the elraglusib arm have now passed the 24-month mark on first-line treatment as of November 2025, while zero patients remain on standard chemotherapy alone at that timepoint — a nearly five-fold difference in 24-month survival. Daraxonrasib takes a fundamentally different approach by directly targeting KRAS mutations, which drive roughly 90% of pancreatic cancers.
In the KRAS G12X subset of previously treated patients, the drug achieved a median progression-free survival of 8.5 months and a median overall survival of 14.5 months, with an 89% six-month overall survival landmark. The disease control rate hit 91% in that subgroup. Revolution Medicines has completed enrollment in its Phase 3 RASolute-302 trial, with results expected later in 2026 — data that could fundamentally change how second-line pancreatic cancer is treated. For context, the standard first-line chemotherapy regimens for metastatic pancreatic cancer — FOLFIRINOX and gemcitabine/nab-paclitaxel — have produced median overall survival figures hovering between 8 and 11 months for years. Any drug that reliably extends survival beyond those benchmarks, or that works in patients whose cancer has already progressed through first-line treatment, represents a meaningful step forward.
How Optune Pax Became the First FDA-Approved Advance in Nearly Three Decades
The FDA’s approval of Optune Pax, developed by Novocure, marks a significant milestone for locally advanced pancreatic cancer — a stage where the tumor has grown into nearby structures but has not yet spread to distant organs. The Phase 3 PANOVA-3 trial demonstrated that adding tumor treating fields to gemcitabine and nab-paclitaxel improved median overall survival from 14.2 months to 16.2 months, with a hazard ratio of 0.82 and a p-value of .039. One-year survival rates climbed from 60.2% to 68.1%. The device itself is a portable, wearable system that delivers low-intensity alternating electric fields at 150 kHz to the tumor region, disrupting cancer cell division. It does not involve radiation or systemic drugs, which means its side effect profile differs from conventional treatments. Systemic toxicity was minimal, but skin irritation under the electrode arrays was common, affecting 76.3% of patients.
An important additional finding was improved pain-free survival with the combination (hazard ratio 0.74, p = .027), which matters enormously for quality of life in a disease notorious for causing severe abdominal pain. However, families should understand the practical realities of this device. It must be worn for extended periods each day to be effective, which creates a real burden for patients who are already fatigued and managing multiple symptoms. For caregivers — particularly those who are also supporting a loved one with dementia or cognitive decline — adding a wearable medical device to the daily routine introduces another layer of complexity. The survival benefit, while statistically significant, is measured in months rather than years. Whether those additional months justify the discomfort and logistical challenges of the device is a deeply personal calculation that each patient and family must make with their oncology team.
The KRAS Revolution and What It Means for Targeted Pancreatic Cancer Treatment
KRAS mutations have been called “undruggable” for decades, a source of frustration given that these mutations are present in the vast majority of pancreatic cancers. That label is finally becoming outdated. Daraxonrasib is a RAS(ON) multi-selective inhibitor, meaning it targets the active form of multiple KRAS variants rather than a single mutation. In its Phase 1 study, more than 90% of 83 patients experienced disease stabilization, approximately 30% saw measurable tumor shrinkage, and at least half gained more than eight months before their cancer progressed. The overall response rate was 36% in the KRAS G12X subgroup, with a disease control rate of 91%.
The FDA’s decision to grant both Breakthrough Therapy Designation and Orphan Drug Designation (the latter in October 2025) signals regulatory confidence in the drug’s potential. breakthrough designation means the FDA will expedite its review process, which could accelerate availability for patients who currently have limited options after first-line treatment fails. Adding to this momentum, a novel KRAS G12D inhibitor called INCB161734 was presented at ASCO GI 2026, showing disease control in nearly 80% of patients with heavily pretreated advanced or metastatic KRAS G12D-mutated pancreatic cancer. This is an early-phase result and should be interpreted with appropriate caution — response rates in small, early trials often shrink in larger studies. But the fact that multiple drugs are now successfully targeting different KRAS variants suggests that the therapeutic bottleneck around this mutation is genuinely breaking open.
Comparing Survival Numbers Across Treatments — What Patients and Families Should Actually Expect
It is tempting to line up the survival statistics from each trial and pick the drug with the best numbers, but that comparison is misleading without understanding the patient populations involved. Elraglusib’s results come from previously untreated metastatic patients — people receiving their first chemotherapy regimen. Daraxonrasib’s most impressive numbers come from previously treated patients with specific KRAS mutations who had already failed at least one line of therapy. Optune Pax was studied in locally advanced disease, not metastatic, which carries a different baseline prognosis. These are fundamentally different clinical scenarios.
Immuneering Corporation’s atebimetinib, a MEK inhibitor, reported 86% overall survival at nine months in first-line pancreatic cancer patients when combined with modified gemcitabine/nab-paclitaxel. The company described the results as “extraordinary,” and while that characterization is understandable given the disease, the data is still early and the patient numbers have not been fully reported. Without a randomized comparison arm, it is difficult to know how much of that benefit comes from the drug versus patient selection or other factors. For families making treatment decisions — especially those already managing cognitive decline or dementia alongside a cancer diagnosis — the relevant question is not which drug has the highest survival number on paper, but which treatment approach fits the patient’s specific cancer biology, prior treatment history, functional status, and caregiving situation. A drug that requires frequent clinic visits for infusions may not be practical for a patient whose caregiver is also managing someone with advanced dementia. These tradeoffs are real and deserve honest conversation with the treatment team.
Side Effects, Cognitive Concerns, and the Caregiver Burden
The safety profiles of these new treatments vary considerably. Elraglusib’s most notable adverse events at its studied dose of 9.3 mg/kg were visual impairment and neutropenia — the latter being a reduction in white blood cells that increases infection risk. Visual changes are particularly concerning for patients who also have cognitive impairment, as new visual disturbances can exacerbate confusion, increase fall risk, and complicate communication with caregivers who may struggle to determine whether a behavioral change stems from the cancer treatment, the underlying dementia, or disease progression. Chemotherapy-related cognitive impairment, colloquially known as “chemo brain,” is already a well-documented phenomenon that can include memory problems, difficulty concentrating, and slowed processing speed.
For patients who enter treatment with existing cognitive vulnerabilities — whether from age, early-stage dementia, or prior neurological conditions — the additive effects of chemotherapy on brain function deserve careful baseline assessment and ongoing monitoring. None of these pancreatic cancer trials specifically reported cognitive outcomes, which represents a gap in the data that is particularly relevant for older patients. Caregivers navigating both cancer treatment and cognitive decline in their loved ones face compounding demands: managing medication schedules for multiple conditions, interpreting behavioral changes that could stem from several causes, and making surrogate decisions about treatment continuation when the patient can no longer fully participate in those choices. The arrival of more effective pancreatic cancer treatments is genuinely good news, but it also means that patients may live longer with their disease, extending the period of intensive caregiving.
How Immune Activation From New Drugs Could Affect Brain Health
One of the more scientifically intriguing aspects of elraglusib is its apparent ability to activate the immune system within the tumor microenvironment. The elevated CD8+ T cells, NK cells, and Granzyme B+ cells observed in treated tumors suggest the drug is converting immunologically “cold” pancreatic tumors into something the immune system can recognize and attack. This is notable because pancreatic cancer has historically been resistant to immunotherapy approaches that have transformed outcomes in other cancers like melanoma and lung cancer.
For readers following brain health research, the intersection of immune activation and neurological function is an active area of study. Systemic immune activation can affect the central nervous system through inflammatory cytokines that cross the blood-brain barrier. Whether the specific immune changes induced by elraglusib have any neurological implications — positive or negative — is unknown and was not studied in the current trials. This is worth discussing with an oncologist, particularly for patients with pre-existing neuroinflammatory conditions.
What Comes Next — Trials to Watch and the Changing Outlook
The most consequential near-term event is the readout of Revolution Medicines’ Phase 3 RASolute-302 trial for daraxonrasib, expected in 2026. If the Phase 1 results hold up in a larger, randomized study, the drug could become a new standard of care for KRAS-mutant pancreatic cancer after first-line treatment — a space where there are currently few good options. Elraglusib will also need to demonstrate its benefits in a Phase 3 trial before it can gain FDA approval, but the strength and consistency of the Phase 2 data make it a compelling candidate for advancement. What distinguishes this moment from past waves of cautious optimism in pancreatic cancer is the diversity of approaches showing results simultaneously.
A GSK-3β inhibitor that activates the immune system, direct KRAS inhibitors attacking the most common oncogenic driver, a wearable device delivering electric fields, and MEK inhibitors targeting downstream signaling — these are not incremental variations on the same theme. They represent fundamentally different strategies, and the fact that several are producing survival benefits at the same time suggests that the field has turned a genuine corner. For patients and families, this does not erase the grim reality that pancreatic cancer remains among the deadliest malignancies. But it does mean that the conversation with your oncologist in 2026 includes options that simply did not exist two years ago.
Conclusion
The emergence of multiple pancreatic cancer drugs showing real survival benefits — elraglusib doubling 12-month survival, daraxonrasib achieving 14.5-month median overall survival in pretreated KRAS-mutant patients, and Optune Pax earning the first FDA approval for locally advanced disease in nearly 30 years — represents a meaningful inflection point. These are not marginal gains dressed up in press releases. They are statistically significant improvements backed by randomized data, immune correlates, and in one case, regulatory approval.
For families managing the intersection of cancer and cognitive health, these advances carry both promise and complexity. Longer survival means more time with loved ones, but also a longer period of treatment-related side effects, caregiving demands, and difficult decisions. The practical advice remains consistent: ask your oncology team about molecular testing for KRAS mutations, inquire whether any of these agents are available through clinical trials at your treatment center, and have honest conversations about how treatment intensity aligns with your family’s capacity and goals. Progress in pancreatic cancer is finally, cautiously, real — and knowing what to ask about is the first step toward benefiting from it.
Frequently Asked Questions
Is elraglusib available to patients now?
Elraglusib is not yet FDA-approved. It showed promising results in a Phase 2 trial presented at ASCO GI 2026, but it will need to demonstrate benefits in a Phase 3 trial before it can be approved and widely prescribed. Patients may be able to access it through clinical trials — ask your oncologist about eligibility.
What is the difference between locally advanced and metastatic pancreatic cancer, and why does it matter for treatment options?
Locally advanced means the cancer has grown into nearby blood vessels or organs but has not spread to distant sites, while metastatic means it has spread to other parts of the body like the liver or lungs. Optune Pax is approved specifically for locally advanced disease, while elraglusib and daraxonrasib have been studied primarily in metastatic patients. The distinction determines which treatments apply to your situation.
Should every pancreatic cancer patient get genetic testing for KRAS mutations?
Molecular profiling, including KRAS mutation testing, is increasingly considered standard for pancreatic cancer patients. With daraxonrasib and INCB161734 specifically targeting KRAS variants, knowing your mutation status could open the door to targeted therapies or clinical trials that would otherwise be missed.
Can these new treatments be combined with each other?
Currently, these drugs have been studied individually in combination with standard chemotherapy, not with each other. Whether combining approaches — for instance, a KRAS inhibitor with tumor treating fields — would be safe or effective is unknown and would require dedicated clinical trials.
Are there specific cognitive side effects from these new pancreatic cancer drugs?
None of the current trials specifically reported cognitive outcomes. Elraglusib’s noted side effects include visual impairment and neutropenia. The chemotherapy backbone of gemcitabine and nab-paclitaxel carries its own risk of cognitive effects. Patients with pre-existing cognitive concerns should discuss baseline neurological assessment with their care team before starting treatment.
How does Optune Pax physically work, and is it difficult to use at home?
Optune Pax is a portable device that delivers low-intensity alternating electric fields through electrode arrays placed on the skin over the tumor area. It must be worn for extended periods daily. The most common side effect is skin irritation under the arrays, affecting about 76% of patients. The device adds logistical complexity to daily life, which is an important consideration for patients and caregivers already managing other health conditions.
